Hot Features
Premium
Level up your trading with our powerful tools and real-time insights all in one place.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Zymeworks Inc | ZYME | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 8.58 | 03:01:34 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 8.58 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 6.015 - 13.14 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| - | 0 | US$ 8.58 | USD |
Zymeworks Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 453.75M | 70.57M | - | 76.3M | -118.67M | -1.68 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Zymeworks News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ZYME Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 8.71 | 8.71 | 7.97 | 8.35 | 634,038 | -0.13 | -1.49% |
| 1 Month | 9.20 | 9.98 | 7.97 | 8.89 | 590,510 | -0.62 | -6.74% |
| 3 Months | 11.40 | 13.14 | 7.97 | 10.43 | 594,005 | -2.82 | -24.74% |
| 6 Months | 7.04 | 13.14 | 6.83 | 10.04 | 527,485 | 1.54 | 21.88% |
| 1 Year | 8.45 | 13.14 | 6.015 | 8.94 | 516,299 | 0.13 | 1.54% |
| 3 Years | 6.38 | 13.14 | 6.015 | 8.77 | 619,321 | 2.20 | 34.48% |
| 5 Years | 6.38 | 13.14 | 6.015 | 8.77 | 619,321 | 2.20 | 34.48% |
Zymeworks Description
| Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of differentiated product candidates. Its lead clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas. |
